PET imaging of high-affinity a4b2 nicotinic acetylcholine receptors in humans with 18F-AZAN, a radioligand with optimal brain kinetics

Journal of Nuclear Medicine

Volumn 54, Issue 8, 2013, Pages 1308-1314

  Wong, Dean F ^a,b,c   Kuwabara, Hiroto ^a   Kim, Jongho ^a   Brašić, James R ^a   Chamroonrat, Wichana ^a   Gao, Yongjun ^a   Valentine, Heather ^a   Willis, William ^a   Mathur, Anil ^a   McCaul, Mary E ^a   Wand, Gary ^a   Gean, Emily G ^a   Dannals, Robert F ^a   Horti, Andrew G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b The Johns Hopkins University   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Human neuroimaging; Nicotinic receptors; PET

Indexed keywords

2 (6 FLUORO 2,3' BIPYRIDIN 5'YL) 7 METHYL 7 AZA BICYCLO[2.2.1]HEPTANE F 18; NICOTINIC RECEPTOR ALPHA4BETA2; RADIOLIGAND; TRACER; UNCLASSIFIED DRUG; VARENICLINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; BRAIN REGION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMAGE RECONSTRUCTION; KINETICS; MALE; MOUSE; NEUROIMAGING; NONHUMAN; NORMAL HUMAN; OPTIMAL BRAIN KINETICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIOACTIVITY; REPRODUCIBILITY; TEST RETEST RELIABILITY; THALAMUS; WHOLE BODY RADIATION;

HUMAN NEUROIMAGING; NICOTINIC RECEPTORS; PET;

2,2'-DIPYRIDYL; ADULT; ANIMALS; AZABICYCLO COMPOUNDS; BENZAZEPINES; BINDING, COMPETITIVE; BRAIN; FEMALE; HUMANS; KINETICS; LIGANDS; MALE; MIDDLE AGED; NICOTINE; NICOTINIC AGONISTS; PAPIO; POSITRON-EMISSION TOMOGRAPHY; QUINOXALINES; RADIOMETRY; RECEPTORS, NICOTINIC; REPRODUCIBILITY OF RESULTS;

EID: 84881398782     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.108001     Document Type: Article

References (39)

1. Pimlott SL, Piggott M, Owens J, et al. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[125I]-a-85380. Neuropsychopharmacology. 2004;29:108-116.
2. Holladay MW, Dart MJ, Lynch JK. Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J Med Chem. 1997;40:4169-4194.
3. Paterson D, Nordberg A. Neuronal nicotinic receptors in the human brain. Prog Neurobiol. 2000;61:75-111.
4. Picard F, Bruel D, Servent D, et al. Alteration of the in vivo nicotinic receptor density in ADNFLE patients: a PET study. Brain. 2006;129:2047-2060.
5. Brody AL, Mandelkern MA, Costello MR, et al. Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette. Int J Neuropsychopharmacol. 2009;12:305-316.
6. Lukas RJ, Changeux JP, Le Novere N, et al. International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol Rev. 1999;51:397-401.
7. 18F]FA) in the living human brain of smokers with paranoid schizophrenia. Synapse. 2012;66:352-368.
8. Horti AG, Villemagne VL. The quest for Eldorado: development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain. Curr Pharm Des. 2006;12:3877-3900.
9. Gündisch D. Nicotinic acetylcholine receptors and imaging. Curr Pharm Des. 2000;6:1143-1157.
10. SihverW, Langstrom B, Nordberg A. Ligands for in vivo imaging of nicotinic receptor subtypes in Alzheimer brain. Acta Neurol Scand Suppl. 2000;176(suppl):27-33.
11. Sihver W, Nordberg A, Langstrom B, et al. Development of ligands for in vivo imaging of cerebral nicotinic receptors. Behav Brain Res. 2000;113:143-157.
12. Volkow ND, Ding YS, Fowler JS, Gatley SJ. Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia. Biol Psychiatry. 2001;49:211-220.
13. 18F]fluoro-A-85380, a new PET tracer for the nicotinic acetylcholine receptor: studies in the human brain and in vivo demonstration of specific binding in white matter. Synapse. 2004;53:184-189.
14. Horti AG, Wong DF. Clinical perspective and recent development of PET radioligands for imaging cerebral nicotinic acetylcholine receptors. PET Clin. 2009; 4:89-100.
15. Horti AG, Gao Y, Kuwabara H, Dannals RF. Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography. Life Sci. 2010;86:575-584.
16. 18F]F-A85380. Neuroimage. 2008;39:717-727.
17. 18F]fluoropyridin-2-yl)-59-pyridinyl]-7-azabicyclo[2.2.1]heptane, a radiolabeled antagonist for cerebral nicotinic acetylcholine receptor (alpha4beta2-nAChR) with optimal positron emission tomography imaging properties. J Med Chem. 2008;51:4751-4764.
18. Kuwabara H, Wong DF, Gao Y, et al. PET imaging of nicotinic acetylcholine receptors in baboons with 18F-AZAN, a radioligand with improved brain kinetics. J Nucl Med. 2012;53:121-129.
19. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533-1539.
20. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
21. Sossi V, de Jong HWAM, Barker WC, et al. The second generation HRRT: a multi-centre scanner performance investigation. IEEE Nucl Sci Sym Conf Record. 2005;4:2195-2199.
22. Rahmim A, Cheng JC, Blinder S, Camborde ML, Sossi V. Statistical dynamic image reconstruction in state-of-the-art high-resolution PET. Phys Med Biol. 2005;50:4887-4912.
23. Fischl B, van der Kouwe A, Destrieux C, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex. 2004;14:11-22.
24. Patenaude B, Smith SM, Kennedy DN, Jenkinson M. A Bayesian model of shape and appearance for subcortical brain segmentation. Neuroimage. 2011;56:907-922.
25. Ashburner J, Friston KJ. Rigid body registration. In: Frackowiak RSJ, Friston KJ, Frith C, et al., eds. Human Brain Function. 2nd ed. Oxford, U.K.: Academic Press; 2003:635-654.
26. 11C-methyl]-(2)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990; 10:740-747.
27. 11C]DASB: test-retest reproducibility using a multilinear reference tissue parametric imaging method. J Nucl Med. 2006;47:208-214.
28. 11C]PE2I: quantitative modeling and test-retest reproducibility. J Cereb Blood Flow Metab. 2008;28:1059-1069.
29. Ding YS, Fowler J. New-generation radiotracers for nAChR and NET. Nucl Med Biol. 2005;32:707-718.
30. Gao Y, Horti AG, Kuwabara H, et al. Derivatives of (2)-7-methyl-2-(5- (pyridinyl) pyridin-3-yl)-7-azabicyclo[2.2.1]heptane are potential ligands for positron emission tomography imaging of extrathalamic nicotinic acetylcholine receptors. J Med Chem. 2007;50:3814-3824.
31. Zhang Y, Pavlova OA, Chefer SI, et al. 5-substituted derivatives of 6-halogeno-3-((2-(S)-azetidinyl)methoxy)pyridine and 6-halogeno-3-((2-(S)- pyrrolidinyl) methoxy)pyridine with low picomolar affinity for a4b2 nicotinic acetylcholine receptor and wide range of lipophilicity: potential probes for imaging with positron emission tomography. J Med Chem. 2004;47:2453-2465.
32. Brown LL, Kulkarni S, Pavlova OA, et al. Synthesis and evaluation of a novel series of 2-chloro-5-((1-methyl-2-(S)-pyrrolidinyl)methoxy)-3-(2-(4- pyridinyl) vinyl) pyridine analogues as potential positron emission tomography imaging agents for nicotinic acetylcholine receptors. J Med Chem. 2002;45:2841-2849.
33. 18F]fluoro-A-85380 and its metabolites in human blood during PET investigation: a methodological study. Nucl Med Biol. 2007; 34:331-342.
34. Mukhin AG, Kimes AS, Chefer SI, et al. Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380. J Nucl Med. 2008;49:1628-1635.
35. 11C]OMAR. Neuroimage. 2010;52:1505-1513.
36. 11C-ABP688. J Nucl Med. 2007; 48:247-252.
37. 18F]fluoro-A-85380 PET study. Neurobiol Learn Mem. 2008;90:404-412.
38. 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. Psychopharmacology (Berl). 2006;188: 509-520.
39. Lotfipour S, Mandelkern M, Alvarez-Estrada M, Brody A. A single administration of low-dose varenicline saturates a4b2* nicotinic acetylcholine receptors in the human brain. Neuropsychopharmacology. 2012;37:1738-1748.